(Note: This is a unit offering with KTTA as the proposed symbol for the common stock and KTTAW for the warrants.)  We are a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, […]

We intend to focus our search for a target business operating in data infrastructure and analytics, with a primary focus on space and wireless industries and related technology and services, which we refer to as “space-based tech” businesses. (Incorporated in the Cayman Islands)  (Note: Endurance Acquisition Corp. priced its SPAC IPO on Sept. 14, 2021, in […]

We intend to partner with a tech-enabled company based in the U.S. or Canada. We believe there are numerous partners operating in the technology and technology-enabled industries that are well-advantaged and highly scalable with the right guidance from an acquisition partner. We are targeting a company valued between approximately $1 billion and $5 billion that has a […]

We are a trusted global provider of value-added solutions to many of the world’s leading brands in the beauty, personal care and home care categories. We partner closely with both industry-leading consumer products companies and fast-growing independent brands as a critical enabler of their success through ideation, formulation, design, packaging and manufacturing of products sold […]

We intend to focus on operating businesses in and around the new energy, biotech, and education industries in Asia (excluding China). We shall not undertake our initial business combination with any entity with its principal business operations in China (including Hong Kong and Macau).

We currently intend to concentrate our efforts in identifying high quality businesses that have recently undergone a restructuring. Our management team and Marblegate, an affiliate of our sponsor, have extensive experience investing in post-restructured companies. We believe that this experience makes us very well situated to identify, source, negotiate and execute a business combination at […]

We intend to focus our search on businesses in the customer engagement sector of telecommunications, retail and financial services.  Subash Menon, our CEO and chairman of the board, is also the CEO and co-founder of Pelatro (LON: PTRO), a Customer Engagement enterprise software company listed on the Alternative Investment Market (“AIM”) and the London Stock […]

We intend to capitalize on our management team’s background and experience to identify promising opportunities that are at the forefront of smart health technology and are enabling innovative solutions that support the transformation to value-based, precision healthcare. Specifically, we are pursuing scale-up stage operating companies that leverage modern data science to make healthcare more effective, […]

We are a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The widespread availability of approved targeted oncology treatments, such as kinase inhibitors, has transformed the cancer treatment landscape. Despite the therapeutic benefit that targeted oncology treatments have created for some patients, the response […]

(Note: The company will change its name to DICE Therapeutics, Inc., from DiCE Molecules Holdings, LLC,  before the effectiveness of the registration statement, the prospectus says.) We are a biopharmaceutical company leveraging our proprietary technology platform, which we refer to as DELSCAPE, to build a pipeline of novel oral therapeutic candidates to treat chronic diseases […]